Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation

Journal of Lipid Research

Volumn 55, Issue 11, 2014, Pages 2334-2342

  Jarrar, Yazun Bashir ^a   Cha, Eun Young ^a   Seo, Kyung Ah ^a   Ghim, Jong Lyul ^a   Kim, Hyo Ji ^a   Kim, Dong Hyun ^a   Lee, Su Jun ^a   Shin, Jae Gook ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; GENOMIC DNA; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; RECOMBINANT ENZYME; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; GLUCURONIC ACID; HYDROXYICOSATETRAENOIC ACID; ISOENZYME;

ADULT; ARTICLE; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; GENETICS; KINETICS; METABOLISM;

ADULT; GENETIC VARIATION; GENOTYPE; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; ISOENZYMES; KINETICS; MICROSOMES, LIVER;

EID: 84918771388     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M051169     Document Type: Article

References (37)

1. Zordoky, B. N., and A. O. El-Kadi. 2010. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol. Ther. 125: 446-463.
2. Konkel, A., and W. H. Schunck. 2011. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim. Biophys. Acta. 1814: 210-222.
3. Devos, A., C. L. Lino Cardenas, F. Glowacki, A. Engels, J. M. Lo-Guidice, D. Chevalier, D. Allorge, F. Broly, and C. Cauffiez. 2010. Genetic polymorphism of CYP2U1, a cytochrome P450 involved in fatty acids hydroxylation. Prostaglandins Leukot. Essent. Fatty Acids. 83: 105-110.
4. Miyata, N., and R. J. Roman. 2005. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J. Smooth Muscle Res. 41: 175-193.
5. Wu, C. C., and M. L. Schwartzman. 2011. The role of 20-HETE in androgen-mediated hypertension. Prostaglandins Other Lipid Mediat. 96: 45-53.
6. Liu, J. Y., N. Li, J. Yang, H. Qiu, D. Ai, N. Chiamvimonvat, Y. Zhu, and B. D. Hammock. 2010. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc. Natl. Acad. Sci. USA. 107: 17017-17022.
7. Baines, A. D., and P. Ho. 2005. 20-HETE-mediated vasoconstriction by hemoglobin-O2 carrier in Sprague-Dawley but not Wistar rats. J. Appl. Physiol. 98: 772-779.
8. Vasudevan, H., V. G. Yuen, and J. H. McNeill. 2012. Testosterone-dependent increase in blood pressure is mediated by elevated Cyp4A expression in fructose-fed rats. Mol. Cell. Biochem. 359: 409-418.
9. Ward, N. C., J. Rivera, J. Hodgson, I. B. Puddey, L. J. Beilin, J. R. Falck, and K. D. Croft. 2004. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation. 110: 438-443.
10. Mayer, B., W. Lieb, A. Gotz, I. R. Konig, Z. Aherrahrou, A. Thiemig, S. Holmer, C. Hengstenberg, A. Doering, H. Loewel, et al. 2005. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension. 46: 766-771.
11. Liu, H., Y. Zhao, D. Nie, J. Shi, L. Fu, Y. Li, D. Yu, and J. Lu. 2008. Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. J. Am. Soc. Nephrol. 19: 714-721.
12. Williams, J. M., S. Murphy, M. Burke, and R. J. Roman. 2010. 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 56: 336-344.
13. Watzer, B., S. Reinalter, H. W. Seyberth, and H. Schweer. 2000. Determination of free and glucuronide conjugated 20-hydroxyarachidonic acid (20-HETE) in urine by gas chromatography/negative ion chemical ionization mass spectrometry. Prostaglandins Leukot. Essent. Fatty Acids. 62: 175-181.
14. Ward, N. C., I. B. Puddey, J. M. Hodgson, L. J. Beilin, and K. D. Croft. 2005. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic. Biol. Med. 38: 1032-1036.
15. Pat Kunert, M., and I. Drenjancevic. 2011. 20-Hydroxyeicosatetraenoic acid, endothelial dysfunction and hypertension. Med. Glas. (Zenica). 8: 170-180.
16. Williams, J. M., A. Sarkis, B. Lopez, R. P. Ryan, A. K. Flasch, and R. J. Roman. 2007. Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension. 49: 687-694.
17. Lohr, J. W., G. R. Willsky, and M. A. Acara. 1998. Renal drug metabolism. Pharmacol. Rev. 50: 107-141.
18. Tukey, R. H., and C. P. Strassburg. 2000. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40: 581-616.
19. Court, M. H. 2010. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab. Rev. 42: 209-224.
20. Guillemette, C. 2003. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3: 136-158.
21. Turgeon, D., S. Chouinard, P. Belanger, S. Picard, J. F. Labbe, P. Borgeat, and A. Belanger. 2003. Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases. J. Lipid Res. 44: 1182-1191.
22. Lee, S. J., S. S. Lee, H. J. Jung, H. S. Kim, S. J. Park, C. W. Yeo, and J. G. Shin. 2009. Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab. Dispos. 37: 1464-1470.
23. Seo, K. A., S. K. Bae, Y. K. Choi, C. S. Choi, K. H. Liu, and J. G. Shin. 2010. Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab. Dispos. 38: 2007-2013.
24. Little, J. M., M. Kurkela, J. Sonka, S. Jantti, R. Ketola, S. Bratton, M. Finel, and A. Radominska-Pandya. 2004. Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases. J. Lipid Res. 45: 1694-1703.
25. King, C., W. Tang, J. Ngui, T. Tephly, and M. Braun. 2001. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol. Sci. 61: 49-53.
26. Chen, Y., S. Chen, X. Li, X. Wang, and S. Zeng. 2006. Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population. Drug Metab. Dispos. 34: 1462-1467.
27. Hwang, M. S., S. J. Lee, H. E. Jeong, S. Lee, M. A. Yoo, and J. G. Shin. 2010. Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population. Drug Metab. Pharmacokinet. 25: 398-402.
28. Yea, S. S., S. S. Lee, W. Y. Kim, K. H. Liu, H. Kim, J. H. Shon, I. J. Cha, and J. G. Shin. 2008. Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther. Drug Monit. 30: 23-34.
29. Saito, Y., K. Sai, K. Maekawa, N. Kaniwa, K. Shirao, T. Hamaguchi, N. Yamamoto, H. Kunitoh, Y. Ohe, Y. Yamada, et al. 2009. Close association of UGT1A9 IVS1+399C>T with UGT1A1∗28, ∗6, or ∗60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab. Dispos. 37: 272-276.
30. Girard, H., L. Villeneuve, M. H. Court, L. C. Fortier, P. Caron, Q. Hao, L. L. von Moltke, D. J. Greenblatt, and C. Guillemette. 2006. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos. 34: 1220-1228.
31. Sacerdoti, D., M. Balazy, P. Angeli, A. Gatta, and J. C. McGiff. 1997. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J. Clin. Invest. 100: 1264-1270.
32. Debinski, H. S., P. I. Mackenzie, C. S. Lee, M. L. Mashford, J. A. Danks, T. R. Tephly, M. Green, and P. V. Desmond. 1996. UDP glucuronosyltransferase in the cirrhotic rat liver. J. Gastroenterol. Hepatol. 11: 373-379.
33. Yamanaka, H., M. Nakajima, M. Katoh, Y. Hara, O. Tachibana, J. Yamashita, H. L. McLeod, and T. Yokoi. 2004. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9∗22) and its effects on the transcriptional activity. Pharmacogenetics. 14: 329-332.
34. Thibaudeau, J., J. Lepine, J. Tojcic, Y. Duguay, G. Pelletier, M. Plante, J. Brisson, B. Tetu, S. Jacob, L. Perusse, et al. 2006. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 66: 125-133.
35. Parmar, S., J. C. Stingl, A. Huber-Wechselberger, A. Kainz, W. Renner, U. Langsenlehner, P. Krippl, J. Brockmoller, and E. Haschke-Becher. 2011. Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Res. 13: R57.
36. Daly, A. K., G. P. Aithal, J. B. Leathart, R. A. Swainsbury, T. S. Dang, and C. P. Day. 2007. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 132: 272-281.
37. Duguay, Y., C. Baar, F. Skorpen, and C. Guillemette. 2004. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther. 75: 223-233.